［1］Thiery JP. Epithelial-mesenchymal transitions in tumour progression［J］. Nat Rev Cancer,2002,2(6):442-454.
［2］殷涛,王春友,赵刚,等. Snail在胰腺癌中的表达及其与上皮_间叶转化的关系［J］. 中华实验外科杂志，2006,23(6):695-696.
［3］Nohe A, Keating E, Knaus P, et al. Signal transduction of bone morphogenetic protein receptors［J］. Cell Signal, 2004,16(3):291-299.
［4］Lee HS, Lee HK, Kim HS, et al. Tumour suppressor gene expression correlates with gastric cancer prognosis［J］. J Pathol,2003,200(1):39-46.
［5］Leboy PS. Regulating bone growth and development with bone morphogenetic proteins［J］. Am J Pathol,2006,1068(4):14-18.
［6］Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: Genes, pathways, and networks in a collection of 18000 cancer gene expression profiles［J］. Neoplasia,2007,9(2):166-180.
［7］Hamada S, Satoh K, Hirota M, et al. Bone morphogenetic protein 4 induces epithelial-mesenchymal transition through MSX2 induction on pancreatic cancer cell line［J］. J Cell Physiol,2007,213(3):768-774.
［8］Gordon KJ, Kirkbride KC, How T, et al. Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2［J］. Carcinogenesis,2009,30(2):238-248.
［9］Feeley BT, Krenek L, Liu N, et al. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions［J］. Bone,2006,38(2):154-166.
［10］Schwaninger R, Rentsch CA, Wetterwald A, et al. Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases［J］. Am J Pathol, 2007,170(1):160-175.